167 related articles for article (PubMed ID: 16607967)
1. Genital herpes vaccines--cause for cautious optimism.
Haddow LJ; Mindel A
Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
[TBL] [Abstract][Full Text] [Related]
2. [Vaccines as an approach to the immunocorrection in herpetic infections].
Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
[TBL] [Abstract][Full Text] [Related]
4. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
5. Current status and prospects for development of an HSV vaccine.
Johnston C; Koelle DM; Wald A
Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811
[TBL] [Abstract][Full Text] [Related]
6. Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review.
Bernstein DI
Antiviral Res; 2020 Aug; 180():104821. PubMed ID: 32544409
[TBL] [Abstract][Full Text] [Related]
7. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
[TBL] [Abstract][Full Text] [Related]
8. Development of prophylactic vaccines for genital and neonatal herpes.
Jones CA; Cunningham AL
Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
[TBL] [Abstract][Full Text] [Related]
9. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for herpes simplex virus infections.
Koelle DM
Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
[TBL] [Abstract][Full Text] [Related]
11. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
[TBL] [Abstract][Full Text] [Related]
13. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER
Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279
[TBL] [Abstract][Full Text] [Related]
14. The challenge of developing a herpes simplex virus 2 vaccine.
Dropulic LK; Cohen JI
Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
[TBL] [Abstract][Full Text] [Related]
15. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
Awasthi S; Friedman HM
J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
[No Abstract] [Full Text] [Related]
16. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
17. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Jones CA; Cunningham AL
Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
[TBL] [Abstract][Full Text] [Related]
18. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
Barinskiĭ IF; Makhmudov FR
Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
[TBL] [Abstract][Full Text] [Related]
19. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA
PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus type 2 vaccines: new ground for optimism?
Aurelian L
Clin Diagn Lab Immunol; 2004 May; 11(3):437-45. PubMed ID: 15138167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
